C1-05: Oral talactoferrin extends survival in patients with refractory NSCLC in a randomized, placebo-controlled, phase 2 trial
| Autor: | Parikh, Purvish M., Wang, Yenyun, Ranade, A.A., Vaid, A.K., Advani, S.H., Raghunadharao, D, Nag, S, Madhavan, J.P., Varadhachary, Atul |
|---|---|
| Zdroj: | In Journal of Thoracic Oncology August 2007 2(8) Supplement:S360-S360 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|